| . | PC . | PLN . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | p . |
| Whole (n = 46) | ||||
| HPV species | 0.093 | 0.33 | ||
| α-7 | 4.60 (1.12–18.96) | 2.11 (0.11–39.76) | ||
| α-9(reference) | 1 | 1 | ||
| Negative | 1.72 (0.39–7.46) | 0.47 (0.014–14.16) | ||
| FIGO Stage | 0.45 | 0.19 | ||
| 1,2 (reference) | 1 | 1 | ||
| 3,4 | 1.51 (0.524–4.32) | 0.25 (0.026–2.39) | ||
| Histology SCC (reference) | 1 | 0.9 | 1 | 0.17 |
| Others | 1.08 (0.31–3.81) | 4.24 (0.52–34.69) | ||
| PALN | 0.99 | 0.13 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 1.0 (0.25–4.01) | 4.99 (0.60–41.09) | ||
| HPV positive (n = 31) | ||||
| HPV species | 0.016 | 0.38 | ||
| α-7 | 6.29 (1.47–27.0) | 5.90 (0.35–100.26) | ||
| α-9 (reference) | 1 | 1 | ||
| FIGO Stage | 0.37 | 0.61 | ||
| 1.2 (reference) | 1 | 1 | ||
| 3, 4 | 1.78 (0.50–6.26) | 0.56 (0.058–5.41) | ||
| Histology | 0.57 | 0.61 | ||
| SCC (reference) | 1 | 1 | ||
| Others | 1.67 (0.27–10.15) | 1.80 (0.19–16.8) | ||
| PALN | 0.96 | 0.55 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 0.95 (0.15–6.0) | 2.07 (0.20–21.2) | ||
| . | PC . | PLN . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | p . |
| Whole (n = 46) | ||||
| HPV species | 0.093 | 0.33 | ||
| α-7 | 4.60 (1.12–18.96) | 2.11 (0.11–39.76) | ||
| α-9(reference) | 1 | 1 | ||
| Negative | 1.72 (0.39–7.46) | 0.47 (0.014–14.16) | ||
| FIGO Stage | 0.45 | 0.19 | ||
| 1,2 (reference) | 1 | 1 | ||
| 3,4 | 1.51 (0.524–4.32) | 0.25 (0.026–2.39) | ||
| Histology SCC (reference) | 1 | 0.9 | 1 | 0.17 |
| Others | 1.08 (0.31–3.81) | 4.24 (0.52–34.69) | ||
| PALN | 0.99 | 0.13 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 1.0 (0.25–4.01) | 4.99 (0.60–41.09) | ||
| HPV positive (n = 31) | ||||
| HPV species | 0.016 | 0.38 | ||
| α-7 | 6.29 (1.47–27.0) | 5.90 (0.35–100.26) | ||
| α-9 (reference) | 1 | 1 | ||
| FIGO Stage | 0.37 | 0.61 | ||
| 1.2 (reference) | 1 | 1 | ||
| 3, 4 | 1.78 (0.50–6.26) | 0.56 (0.058–5.41) | ||
| Histology | 0.57 | 0.61 | ||
| SCC (reference) | 1 | 1 | ||
| Others | 1.67 (0.27–10.15) | 1.80 (0.19–16.8) | ||
| PALN | 0.96 | 0.55 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 0.95 (0.15–6.0) | 2.07 (0.20–21.2) | ||
PC: pelvic control
PLN: pelvic lymph node control
PALN: para-aortic lymph node
| . | PC . | PLN . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | p . |
| Whole (n = 46) | ||||
| HPV species | 0.093 | 0.33 | ||
| α-7 | 4.60 (1.12–18.96) | 2.11 (0.11–39.76) | ||
| α-9(reference) | 1 | 1 | ||
| Negative | 1.72 (0.39–7.46) | 0.47 (0.014–14.16) | ||
| FIGO Stage | 0.45 | 0.19 | ||
| 1,2 (reference) | 1 | 1 | ||
| 3,4 | 1.51 (0.524–4.32) | 0.25 (0.026–2.39) | ||
| Histology SCC (reference) | 1 | 0.9 | 1 | 0.17 |
| Others | 1.08 (0.31–3.81) | 4.24 (0.52–34.69) | ||
| PALN | 0.99 | 0.13 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 1.0 (0.25–4.01) | 4.99 (0.60–41.09) | ||
| HPV positive (n = 31) | ||||
| HPV species | 0.016 | 0.38 | ||
| α-7 | 6.29 (1.47–27.0) | 5.90 (0.35–100.26) | ||
| α-9 (reference) | 1 | 1 | ||
| FIGO Stage | 0.37 | 0.61 | ||
| 1.2 (reference) | 1 | 1 | ||
| 3, 4 | 1.78 (0.50–6.26) | 0.56 (0.058–5.41) | ||
| Histology | 0.57 | 0.61 | ||
| SCC (reference) | 1 | 1 | ||
| Others | 1.67 (0.27–10.15) | 1.80 (0.19–16.8) | ||
| PALN | 0.96 | 0.55 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 0.95 (0.15–6.0) | 2.07 (0.20–21.2) | ||
| . | PC . | PLN . | ||
|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | p . |
| Whole (n = 46) | ||||
| HPV species | 0.093 | 0.33 | ||
| α-7 | 4.60 (1.12–18.96) | 2.11 (0.11–39.76) | ||
| α-9(reference) | 1 | 1 | ||
| Negative | 1.72 (0.39–7.46) | 0.47 (0.014–14.16) | ||
| FIGO Stage | 0.45 | 0.19 | ||
| 1,2 (reference) | 1 | 1 | ||
| 3,4 | 1.51 (0.524–4.32) | 0.25 (0.026–2.39) | ||
| Histology SCC (reference) | 1 | 0.9 | 1 | 0.17 |
| Others | 1.08 (0.31–3.81) | 4.24 (0.52–34.69) | ||
| PALN | 0.99 | 0.13 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 1.0 (0.25–4.01) | 4.99 (0.60–41.09) | ||
| HPV positive (n = 31) | ||||
| HPV species | 0.016 | 0.38 | ||
| α-7 | 6.29 (1.47–27.0) | 5.90 (0.35–100.26) | ||
| α-9 (reference) | 1 | 1 | ||
| FIGO Stage | 0.37 | 0.61 | ||
| 1.2 (reference) | 1 | 1 | ||
| 3, 4 | 1.78 (0.50–6.26) | 0.56 (0.058–5.41) | ||
| Histology | 0.57 | 0.61 | ||
| SCC (reference) | 1 | 1 | ||
| Others | 1.67 (0.27–10.15) | 1.80 (0.19–16.8) | ||
| PALN | 0.96 | 0.55 | ||
| Negative (reference) | 1 | 1 | ||
| Positive | 0.95 (0.15–6.0) | 2.07 (0.20–21.2) | ||
PC: pelvic control
PLN: pelvic lymph node control
PALN: para-aortic lymph node
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
